Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

16th International Myeloma Workshop

1 - 4 Mar 2017
Novotel and Pullman Hotel, New Delhi, India
IMW 2017 highlights
Dr Laurent Garderet - Hôpital Saint Antoine, Paris, France
IMW 2017 highlights ( Dr Laurent Garderet - Hôpital Saint Antoine, Paris, France )
7 Mar 2017
Outcome of third salvage autologous stem cell transplantation in multiple myelom...
Dr Laurent Garderet - Hôpital Saint Antoine, Paris, France
Outcome of third salvage autologous stem cell transplantation in multiple myeloma ( Dr Laurent Garderet - Hôpital Saint Antoine, Paris, France )
7 Mar 2017
Treatment of multiple myeloma patients in the relapsed setting: Expert discussio...
Prof Maria-Victoria Mateos, Prof Paul Richardson
Treatment of multiple myeloma patients in the relapsed setting: Expert discussion from IMW 2017 ( Prof Maria-Victoria Mateos, Prof Paul Richardson )
5 Mar 2017
Multiple myeloma highlights from IMW 2017
Prof Phillipe Moreau, Prof Philip McCarthy, Prof Jens Hillengass, Prof Meletios ...
Multiple myeloma highlights from IMW 2017 ( Prof Phillipe Moreau, Prof Philip McCarthy, Prof Jens Hillengass, Prof Meletios Dimopoulos )
4 Mar 2017
Evaluating efficacy of denosumab compared with zoledronic acid in symptomatic my...
Dr Noopar Raje - Massachusetts General Hospital, Boston, USA
Evaluating efficacy of denosumab compared with zoledronic acid in symptomatic myeloma ( Dr Noopar Raje - Massachusetts General Hospital, Boston, USA )
4 Mar 2017
Long term effects of myeloma treatment
Monica Morris - Myeloma UK, Edinburgh, UK
Long term effects of myeloma treatment ( Monica Morris - Myeloma UK, Edinburgh, UK )
3 Mar 2017
Update on CASTOR trial: Daratumumab, bortezomib, and dexamethasone for relapsed ...
Dr Suzanne Lentzsch - Columbia University, New York, USA
Update on CASTOR trial: Daratumumab, bortezomib, and dexamethasone for relapsed or refractory myeloma ( Dr Suzanne Lentzsch - Columbia University, New York, USA )
3 Mar 2017
Caring for multiple myeloma carers
Monica Morris - Myeloma UK, Edinburgh, UK
Caring for multiple myeloma carers ( Monica Morris - Myeloma UK, Edinburgh, UK )
3 Mar 2017
Impact of recurrent myeloma alterations on drug response
Dr Muntasir Mamun Majumder - University of Helsinki, Helsinki, Finland
Impact of recurrent myeloma alterations on drug response ( Dr Muntasir Mamun Majumder - University of Helsinki, Helsinki, Finland )
3 Mar 2017
What is the biology behind immunotherapy for MM?
Dr Alexander Lesokhin - Memorial Sloan Kettering Cancer Center, New York, USA
What is the biology behind immunotherapy for MM? ( Dr Alexander Lesokhin - Memorial Sloan Kettering Cancer Center, New York, USA )
3 Mar 2017
Evolving role of MRD negativity in multiple myeloma
Prof Jesús San Miguel - University Hospital, Salamanca, Spain
Evolving role of MRD negativity in multiple myeloma ( Prof Jesús San Miguel - University Hospital, Salamanca, Spain )
3 Mar 2017
Role of immunotherapy and precision medicines in multiple myeloma and key new gu...
Prof Sagar Lonial - Emory University, Atlanta, USA
Role of immunotherapy and precision medicines in multiple myeloma and key new guidelines ( Prof Sagar Lonial - Emory University, Atlanta, USA )
3 Mar 2017
Carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple mye...
Dr Ralph Boccia - Center for Cancer and Blood Disorders, Bethesda, USA
Carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma ( Dr Ralph Boccia - Center for Cancer and Blood Disorders, Bethesda, USA )
3 Mar 2017
Is precision myeloma medicine more hype than reality?
Dr Suzanne Lentzsch - Columbia University, New York, USA
Is precision myeloma medicine more hype than reality? ( Dr Suzanne Lentzsch - Columbia University, New York, USA )
3 Mar 2017
Asia-Pacific approaches to myeloma trials
Prof Chng Wee Joo - National University Health System, Singapore, Singapore
Asia-Pacific approaches to myeloma trials ( Prof Chng Wee Joo - National University Health System, Singapore, Singapore )
3 Mar 2017
Denosumab vs zoledronic acid for bone disease in newly diagnosed multiple myelom...
Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece
Denosumab vs zoledronic acid for bone disease in newly diagnosed multiple myeloma ( Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece )
3 Mar 2017
Bone disease and management of myeloma complications
Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece
Bone disease and management of myeloma complications ( Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece )
3 Mar 2017
Monoclonal antibodies in multiple myeloma
Prof Maria-Victoria Mateos - University Hospital of Salamanca, Salamanca, Spain
Monoclonal antibodies in multiple myeloma ( Prof Maria-Victoria Mateos - University Hospital of Salamanca, Salamanca, Spain )
2 Mar 2017
Treatment options for newly diagnosed multiple myeloma and management of bone di...
Prof Sonneveld, Prof Cavo, Prof Terpos and Professor Voorhees
Treatment options for newly diagnosed multiple myeloma and management of bone disease: Roundtable at IMW 2017 ( Prof Sonneveld, Prof Cavo, Prof Terpos and Professor Voorhees )
2 Mar 2017
Promising myeloma agents in phase II trials
Dr Ruben Niesvizky - New York Presbyterian Hospital-Weill Cornell Medical Center...
Promising myeloma agents in phase II trials ( Dr Ruben Niesvizky - New York Presbyterian Hospital-Weill Cornell Medical Center, New York, USA )
2 Mar 2017
Ongoing transplant phase III trials for myeloma
Dr Amrita Krishnan - City of Hope Cancer Center, Duarte, USA
Ongoing transplant phase III trials for myeloma ( Dr Amrita Krishnan - City of Hope Cancer Center, Duarte, USA )
2 Mar 2017
Post autologous transplant therapies in high risk multiple myeloma: StaMINA tria...
Dr Amrita Krishnan - City of Hope Cancer Center, Duarte, USA
Post autologous transplant therapies in high risk multiple myeloma: StaMINA trial update ( Dr Amrita Krishnan - City of Hope Cancer Center, Duarte, USA )
2 Mar 2017
Updates from ASPIRE and ENDEAVOR: Multicenter phase III studies of carfilzomib f...
Dr David Siegel - John Theurer Cancer Center, Hackensack, USA
Updates from ASPIRE and ENDEAVOR: Multicenter phase III studies of carfilzomib for relapsed/refractory multiple myeloma ( Dr David Siegel - John Theurer Cancer Center, Hackensack, USA )
2 Mar 2017
Pomalidomide and low-dose dexamethasone for relapsed or refractory multiple myel...
Dr David Siegel - John Theurer Cancer Center, Hackensack, USA
Pomalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma ( Dr David Siegel - John Theurer Cancer Center, Hackensack, USA )
2 Mar 2017
How should we treat smoldering multiple myeloma? Expert discussion from IMW 2017
Prof Maria-Victoria Mateos, Prof Paul Richardson
How should we treat smoldering multiple myeloma? Expert discussion from IMW 2017 ( Prof Maria-Victoria Mateos, Prof Paul Richardson )
2 Mar 2017
Examining strategies to tailor multiple myeloma immunotherapy
Dr Jeffrey Zonder - Karmanos Cancer Institute, Detroit, USA
Examining strategies to tailor multiple myeloma immunotherapy ( Dr Jeffrey Zonder - Karmanos Cancer Institute, Detroit, USA )
2 Mar 2017
Sequencing multiple myeloma using blood tests
Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA
Sequencing multiple myeloma using blood tests ( Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA )
2 Mar 2017